Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
IF YOU ARE AN INVESTOR WHO LOST MONEY ON NOVO NORDISK A/S (NVO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims & Hers Health, Inc. ('Hims') and its weight loss drug, Wegovy, would no longer be available through Hims, stating that Hims 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.'
On this news, Novo Nordisk's stock price fell $4.05, or 5.5%, to close at $69.72 per share on June 23, 2025, thereby injuring investors.
Then, on July 29, 2025, Novo Nordisk cut its previously issued guidance, lowering sales growth from 13-21% to 8-14%, and operating profit from 16-24% to 10-16%. The Company cited lower growth expectations for both Ozempic and Wegovy on the back of a slowdown in market expansion, competition, and the alleged continued use of compounded GLP-1s.
On this news, Novo Nordisk's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 29, 2025, thereby injuring investors further.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding Novo Nordisk should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.
About Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.
With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies
Novo Nordisk (NOVO, Financials) expanded its U.S. legal campaign against makers of unapproved versions of semaglutide the active ingredient in its blockbuster weight?loss and diabetes drugs Wegovy and Ozempic. The Danish drugmaker said Tuesday it filed 14 new lawsuits; the targets include telehealth providers, compounding pharmacies, and medical spas accused of selling compounded semaglutide under the fake guise of personalization. Warning! GuruFocus has detected 1 Warning Sign with NVO. The suits name firms such as Prism Aesthetics, Mochi Health, and Fella Health; some have also appeared in Eli Lilly's (LLY, Financials) litigation over knockoff versions of its weight?loss drug Zepbound. Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in some cases, the products allegedly contain illicit foreign?sourced active pharmaceutical ingredients. Compounders were temporarily allowed to produce semaglutide during a declared shortage; when the U.S. Food and Drug Administration ended that allowance, some companies shifted to offering personalized versions outside the approved drug label. Novo argues the approach violates state laws on corporate practice of medicine; it also raises safety concerns, as the copies have not been proven effective. Industry groups pushed back; Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said Novo's claims misrepresent the work of legitimate, state?licensed pharmacies. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
HubSpot (NYSE:HUBS) Beats Q2 Sales Targets, Full-Year Outlook Slightly Exceeds Expectations
Sales and marketing software maker HubSpot (NYSE:HUBS) announced better-than-expected revenue in Q2 CY2025, with sales up 19.4% year on year to $760.9 million. Guidance for next quarter's revenue was better than expected at $786 million at the midpoint, 1.4% above analysts' estimates. Its non-GAAP profit of $2.19 per share was 3.1% above analysts' consensus estimates. Is now the time to buy HubSpot? Find out in our full research report. HubSpot (HUBS) Q2 CY2025 Highlights: Revenue: $760.9 million vs analyst estimates of $739.3 million (19.4% year-on-year growth, 2.9% beat) Adjusted EPS: $2.19 vs analyst estimates of $2.12 (3.1% beat) Adjusted Operating Income: $129.1 million vs analyst estimates of $124.9 million (17% margin, 3.4% beat) The company lifted its revenue guidance for the full year to $3.08 billion at the midpoint from $3.04 billion, a 1.4% increase Management raised its full-year Adjusted EPS guidance to $9.50 at the midpoint, a 1.8% increase Operating Margin: -3.2%, in line with the same quarter last year Free Cash Flow Margin: 15.3%, down from 16.5% in the previous quarter Customers: 267,982, up from 258,258 in the previous quarter Billings: $785.3 million at quarter end, up 21.2% year on year Market Capitalization: $25.96 billion 'Q2 was another solid quarter of continued revenue growth and customer expansion,' said Yamini Rangan, Chief Executive Officer at HubSpot. Company Overview Started in 2006 by two MIT grad students, HubSpot (NYSE:HUBS) is a software-as-a-service platform that helps small and medium-sized businesses market themselves, sell, and get found on the internet. Revenue Growth Reviewing a company's long-term sales performance reveals insights into its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last three years, HubSpot grew its sales at a decent 23.1% compounded annual growth rate. Its growth was slightly above the average software company and shows its offerings resonate with customers. This quarter, HubSpot reported year-on-year revenue growth of 19.4%, and its $760.9 million of revenue exceeded Wall Street's estimates by 2.9%. Company management is currently guiding for a 17.4% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 14.9% over the next 12 months, a deceleration versus the last three years. Despite the slowdown, this projection is healthy and implies the market is baking in success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Billings Billings is a non-GAAP metric that is often called 'cash revenue' because it shows how much money the company has collected from customers in a certain period. This is different from revenue, which must be recognized in pieces over the length of a contract. HubSpot's billings punched in at $785.3 million in Q2, and over the last four quarters, its growth was impressive as it averaged 20.1% year-on-year increases. This performance aligned with its total sales growth, indicating robust customer demand. The high level of cash collected from customers also enhances liquidity and provides a solid foundation for future investments and growth. Customer Base HubSpot reported 267,982 customers at the end of the quarter, a sequential increase of 9,724. That's roughly in line with what we've observed over the last year, confirming that the company is maintaining its sales momentum. Key Takeaways from HubSpot's Q2 Results We enjoyed seeing HubSpot beat analysts' billings expectations this quarter. We were also glad its full-year EPS guidance slightly exceeded Wall Street's estimates. Overall, we think this was a decent quarter with some key metrics above expectations. The stock traded up 4.4% to $512 immediately following the results. HubSpot put up rock-solid earnings, but one quarter doesn't necessarily make the stock a buy. Let's see if this is a good investment. We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
DoorDash (NASDAQ:DASH) Posts Better-Than-Expected Sales In Q2, Increases Its Orders
On-demand food delivery service DoorDash (NYSE:DASH) beat Wall Street's revenue expectations in Q2 CY2025, with sales up 24.9% year on year to $3.28 billion. Its GAAP profit of $0.65 per share was 49.5% above analysts' consensus estimates. Is now the time to buy DoorDash? Find out in our full research report. DoorDash (DASH) Q2 CY2025 Highlights: Revenue: $3.28 billion vs analyst estimates of $3.16 billion (24.9% year-on-year growth, 3.8% beat) EPS (GAAP): $0.65 vs analyst estimates of $0.43 (49.5% beat) Adjusted EBITDA: $655 million vs analyst estimates of $639.8 million (19.9% margin, 2.4% beat) EBITDA guidance for Q3 CY2025 is $730 million at the midpoint, above analyst estimates of $716.1 million Operating Margin: 5%, up from -7.6% in the same quarter last year Free Cash Flow Margin: 52.2%, up from 16.3% in the previous quarter Orders: 761 million, up 126 million year on year Market Capitalization: $108.2 billion Company Overview Founded by Stanford students with the intent to build 'the local, on-demand FedEx", DoorDash (NYSE:DASH) operates an on-demand food delivery platform. Revenue Growth A company's long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Thankfully, DoorDash's 28.2% annualized revenue growth over the last three years was exceptional. Its growth surpassed the average consumer internet company and shows its offerings resonate with customers, a great starting point for our analysis. This quarter, DoorDash reported robust year-on-year revenue growth of 24.9%, and its $3.28 billion of revenue topped Wall Street estimates by 3.8%. Looking ahead, sell-side analysts expect revenue to grow 18.9% over the next 12 months, a deceleration versus the last three years. We still think its growth trajectory is attractive given its scale and indicates the market is forecasting success for its products and services. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Orders Request Growth As a gig economy marketplace, DoorDash generates revenue growth by expanding the number of services on its platform (e.g. rides, deliveries, freelance jobs) and raising the commission fee from each service provided. Over the last two years, DoorDash's orders, a key performance metric for the company, increased by 20.3% annually to 761 million in the latest quarter. This growth rate is among the fastest of any consumer internet business and indicates its offerings have significant traction. In Q2, DoorDash added 126 million orders, leading to 19.8% year-on-year growth. The quarterly print isn't too different from its two-year result, suggesting its new initiatives aren't accelerating request growth just yet. Revenue Per Request Average revenue per request (ARPR) is a critical metric to track because it measures how much the company earns in transaction fees from each request. This number also informs us about DoorDash's take rate, which represents its pricing leverage over the ecosystem, or "cut" from each transaction. DoorDash's ARPR growth has been mediocre over the last two years, averaging 3.5%. This isn't great, but the increase in orders is more relevant for assessing long-term business potential. We'll monitor the situation closely; if DoorDash tries boosting ARPR by taking a more aggressive approach to monetization, it's unclear whether requests can continue growing at the current pace. This quarter, DoorDash's ARPR clocked in at $4.32. It grew by 4.2% year on year, slower than its request growth. Key Takeaways from DoorDash's Q2 Results It was great to see DoorDash increase its number of requests this quarter. We were also happy its revenue outperformed Wall Street's estimates. Overall, this print had some key positives. The stock traded up 4.8% to $270.50 immediately following the results. Sure, DoorDash had a solid quarter, but if we look at the bigger picture, is this stock a buy? When making that decision, it's important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it's free.
